Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Capital Expenditures (2022 - 2024)

Historic Capital Expenditures for Addex Therapeutics (ADXN) over the last 3 years, with Q4 2024 value amounting to $1.5 billion.

  • Addex Therapeutics' Capital Expenditures fell 7713.33% to $1.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 billion, marking a year-over-year increase of 201751.88%. This contributed to the annual value of $1447.0 for FY2024, which is 8100.57% down from last year.
  • According to the latest figures from Q4 2024, Addex Therapeutics' Capital Expenditures is $1.5 billion, which was down 7713.33% from $6.4 billion recorded in Q4 2023.
  • Addex Therapeutics' Capital Expenditures' 5-year high stood at $6.4 billion during Q4 2023, with a 5-year trough of -$5.5 billion in Q2 2023.
  • In the last 3 years, Addex Therapeutics' Capital Expenditures had a median value of -$600.56 in 2022 and averaged $217.9 million.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Capital Expenditures was 52731522941.4% (2023), while the steepest drop was 12781281758.46% (2023).
  • Addex Therapeutics' Capital Expenditures (Quarter) stood at $1205.1 in 2022, then skyrocketed by 527315229.41% to $6.4 billion in 2023, then tumbled by 77.13% to $1.5 billion in 2024.
  • Its Capital Expenditures was $1.5 billion in Q4 2024, compared to $6.4 billion in Q4 2023 and -$767.6 million in Q3 2023.